Nurse-Led Home-Based Mobile Health Cardiac Rehabilitation Program for Patients With Chronic Heart Failure: A Randomized Controlled Trial.

ANS Adv Nurs SciJul 7, 2026 (epub)
Clinical ResearchCardiology

Fu-Lan Chang, Tsun-Jui Liu, Yu-Tsung Cheng et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial assessed a nurse-led mobile health intervention for chronic heart failure patients over 12 weeks. The program, which combined wearable activity tracking with weekly coaching, significantly improved daily step count, 6-minute walk distance, metabolic equivalents, and left ventricular ejection fraction compared to usual care.

Key findings

  • The intervention significantly improved daily step count compared to usual care.
  • Participants showed enhanced 6-minute walk distance with the intervention.
  • Metabolic equivalents increased significantly in the intervention group.
  • Left ventricular ejection fraction improved notably with the nurse-led program.

Why it matters

This study demonstrates the potential of nurse-led mobile health interventions to enhance self-care and physical activity in chronic heart failure patients, which may lead to better health outcomes and quality of life.

Source

PubMed · PMID 42406604

Published in ANS Adv Nurs Sci. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.